Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: Arthur Radley who wrote (15814)	2/24/1998 9:32:00 PM
From: Torben Noerup Nielsen	Respond to of 32384

>I don't understand the comment,"periodically draw a random sample >and check out that sample". What sample are you referring to and how >will this determine how the drug is being used for a particular >indication? I'm sorry, I should have been more clear. I believe there is a way of tracking which doctors issue which prescriptions for which drugs. If nothing else, I believe this can be done through the insurance companies (not clear to what extent they will cooperate of course). So take 1,000 prescriptions and trace them back to the doctors to see how many were for one indication and how many were for another. Or something like that. As I said, I would be quite surprised if the contract between LGND and LLY doesn't include a specific mechanism for determining this split of revenues. If it does not, someone messed up and that is not good. Cheers, Torben